Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Generate Biomedicines, Inc.GENB · Entity 1553 | Director | February 26, 2026 | March 02, 2026 |
| Moderna, Inc.MRNA · Entity 2025 | Director · Chief Executive Officer | August 05, 2026 | August 07, 2026 |
| Syros Pharmaceuticals, Inc.SYRS · Entity 85437 | Director | September 15, 2016 | September 19, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Generate Biomedicines, Inc.
Report date February 26, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy OCHA LLC | 724,160 |
Reported balance
After 2026-03-02 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-03-02 · Conversion · Acquired 724,160 · Balance 724,160 F1: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Series A Preferred Stock had no expiration date. F2: Shares held by OCHA LLC, of which the Reporting Person is the controlling unit holder and sole managing member. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-02-25 | Direct | 29,561 |
Reported balance
After 2026-02-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-26 · Grant · Acquired 29,561 · Balance 29,561 F3: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy OCHA LLC | 0 |
Reported balance
After 2026-03-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-02 · Conversion · Disposed 1,100,000 · Balance 0 F1: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Series A Preferred Stock had no expiration date. F2: Shares held by OCHA LLC, of which the Reporting Person is the controlling unit holder and sole managing member. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 460,829 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 460,829 |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Series A Preferred Stock had no expiration date.
F2: Shares held by OCHA LLC, of which the Reporting Person is the controlling unit holder and sole managing member. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F3: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.
Moderna, Inc.
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,440,260 |
Ending reported balance
After 2026-08-06 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-08-05 · Exercise / conversion · Acquired 499,246 · Balance 6,687,037 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. Row 2 · 2026-08-05 · Sale · Disposed 147,473 · Balance 6,539,564 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.58 to $56.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 3 · 2026-08-05 · Sale · Disposed 124,838 · Balance 6,414,726 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.59 to $57.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 4 · 2026-08-05 · Sale · Disposed 39,891 · Balance 6,374,835 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.60 to $58.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 5 · 2026-08-05 · Sale · Disposed 187,044 · Balance 6,187,791 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.61 to $59.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 6 · 2026-08-06 · Exercise / conversion · Acquired 252,469 · Balance 6,440,260 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.15 · Expires 2026-08-10 | Direct | 187,541 |
Reported balance
After 2026-08-05 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-05 · Exercise / conversion · Disposed 370,853 · Balance 187,541 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F8: This option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.15 · Expires 2026-08-10 | Direct | 64,928 |
Reported balance
After 2026-08-05 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-05 · Exercise / conversion · Disposed 128,393 · Balance 64,928 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F8: This option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.15 · Expires 2026-08-10 | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-08-06 · Exercise / conversion · Disposed 187,541 · Balance 0 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F8: This option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.15 · Expires 2026-08-10 | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-08-06 · Exercise / conversion · Disposed 64,928 · Balance 0 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F8: This option is fully vested and exercisable. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 9,210,686 |
Reported balance
Holding disclosure · report date 2026-08-05 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 9,210,686 F6: These shares are owned directly by Boston Biotech Ventures. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,564,880 |
Reported balance
Holding disclosure · report date 2026-08-05 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 6,564,880 F7: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.58 to $56.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.59 to $57.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.60 to $58.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.61 to $59.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6: These shares are owned directly by Boston Biotech Ventures. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F7: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F8: This option is fully vested and exercisable.
Syros Pharmaceuticals, Inc.
Report date September 15, 2016 · Filed September 19, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.59 · Expires 2026-09-14 | Direct | 22,000 |
Reported balance
After 2016-09-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-09-15 · Grant · Acquired 22,000 · Balance 22,000 F1: The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments of 2.77% of the shares underlying the award until the third anniversary of the date of the award, subject to Mr. Bancel's continued service as a director through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments of 2.77% of the shares underlying the award until the third anniversary of the date of the award, subject to Mr. Bancel's continued service as a director through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Aug 7, 2026 20:11 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 64,928 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001682852-26-000153 · form4.xml · derivative · entry 12 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,928 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F8 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 20:11 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 187,541 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001682852-26-000153 · form4.xml · derivative · entry 11 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 187,541 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F8 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 20:11 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 252,469 | $19.15 | $4,834,781.35 |
DisclosureSEC source: 0001682852-26-000153 · form4.xml · nonDerivative · entry 6 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,440,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:11 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 128,393 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001682852-26-000153 · form4.xml · derivative · entry 10 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,928 Underlying: Common Stock · 128,393 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F8 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:11 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 370,853 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001682852-26-000153 · form4.xml · derivative · entry 9 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,541 Underlying: Common Stock · 370,853 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F8 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:11 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 187,044 | $58.79 | $10,996,316.76 |
DisclosureSEC source: 0001682852-26-000153 · form4.xml · nonDerivative · entry 5 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,187,791 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.61 to $59.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:11 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 39,891 | $58.12 | $2,318,464.92 |
DisclosureSEC source: 0001682852-26-000153 · form4.xml · nonDerivative · entry 4 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,374,835 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.60 to $58.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:11 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 124,838 | $56.96 | $7,110,772.48 |
DisclosureSEC source: 0001682852-26-000153 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,414,726 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.59 to $57.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:11 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 147,473 | $56.21 | $8,289,457.33 |
DisclosureSEC source: 0001682852-26-000153 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,539,564 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.58 to $56.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:11 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 499,246 | $19.15 | $9,560,560.90 |
DisclosureSEC source: 0001682852-26-000153 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,687,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 22:50 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries A Preferred Stock · Derivative | 1,100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085881 · ownership.xml · derivative · entry 4 Bancel Stephane · CIK 0001443340 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By OCHA LLC Disclosed balance after: 0 Underlying: Common Stock · 724,160 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Series A Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Series A Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Series A Preferred Stock had no expiration date. F2 · ownership.nature: Shares held by OCHA LLC, of which the Reporting Person is the controlling unit holder and sole managing member. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 22:50 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionCommon Stock | 724,160 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-085881 · ownership.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By OCHA LLC Disclosed balance after: 724,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Series A Preferred Stock had no expiration date. F2 · ownership.nature: Shares held by OCHA LLC, of which the Reporting Person is the controlling unit holder and sole managing member. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:19 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 250,932 | $0.00 Strike: $53.57 | $0.00 |
DisclosureSEC source: 0001682852-26-000044 · form4.xml · derivative · entry 4 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,932 Underlying: Common Stock · 250,932 shares Expires 2036-03-01 F3 · derivative.exercise_date: 25% of this option will vest and become exercisable on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:50 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | GrantStock Option (Right to Buy) · Derivative | 29,561 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085881 · ownership.xml · derivative · entry 3 Bancel Stephane · CIK 0001443340 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,561 Underlying: Common Stock · 29,561 shares Expires 2036-02-25 F3 · derivative.exercise_date: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:23 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 5,450 | $41.99 | $228,845.50 |
DisclosureSEC source: 0001682852-26-000017 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,187,791 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vesting of the 2023 PSUs. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:23 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantCommon Stock | 11,271 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000017 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,193,241 F1 · kind: The reported transaction is the vesting of performance-based restricted stock units granted to the reporting person on February 28, 2023 (the "2023 PSUs"). Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 13:59 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 688,073 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001682852-25-000094 · form4.xml · derivative · entry 4 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 688,073 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person acquired 688,073 shares of the Issuer's common stock upon the exercise in full of a stock option scheduled to expire on February 23, 2026. The option would have been forfeited if not exercised prior to that date. The Reporting Person paid the full exercise price of $7,499,995.70 ($10.90 per share) and applicable withholding taxes of $5,998,279.76 in cash, for a total cash amount of $13,498,275.46. No shares of the Issuer were sold or withheld in connection with the exercise. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 13:59 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 688,073 | $10.90 | $7,499,995.70 |
DisclosureSEC source: 0001682852-25-000094 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,181,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person acquired 688,073 shares of the Issuer's common stock upon the exercise in full of a stock option scheduled to expire on February 23, 2026. The option would have been forfeited if not exercised prior to that date. The Reporting Person paid the full exercise price of $7,499,995.70 ($10.90 per share) and applicable withholding taxes of $5,998,279.76 in cash, for a total cash amount of $13,498,275.46. No shares of the Issuer were sold or withheld in connection with the exercise. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:27 UTC | Moderna, Inc. MRNA · Entity 2025 | PurchaseCommon Stock | 57,493 | $31.53 | $1,812,754.29 |
DisclosureSEC source: 0001127602-25-007916 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 9,210,686 F1 · kind: The transactions reported in this Form 4 represent open market purchases of 160,314 shares of the Issuer's common stock, totaling $5,005,040, by Boston Biotech Ventures, LLC ("Boston Biotech Ventures"), of which the Reporting Person is the majority equity unit holder and the sole managing member. F4 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $31.39 to $31.96. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by Boston Biotech Ventures. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:27 UTC | Moderna, Inc. MRNA · Entity 2025 | PurchaseCommon Stock | 102,821 | $31.04 | $3,191,563.84 |
DisclosureSEC source: 0001127602-25-007916 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 9,153,193 F1 · kind: The transactions reported in this Form 4 represent open market purchases of 160,314 shares of the Issuer's common stock, totaling $5,005,040, by Boston Biotech Ventures, LLC ("Boston Biotech Ventures"), of which the Reporting Person is the majority equity unit holder and the sole managing member. F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $30.38 to $31.38. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by Boston Biotech Ventures. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| March 01, 2025 Filed Mar 3, 2025 21:33 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 357,065 | $0.00 Strike: $30.96 | $0.00 |
DisclosureSEC source: 0001127602-25-007539 · form4.xml · derivative · entry 4 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 357,065 Underlying: Common Stock · 357,065 shares Expires 2035-03-01 F3 · derivative.exercise_date: 25% of this option will vest and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:06 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 6,400 | $30.93 | $197,952.00 |
DisclosureSEC source: 0001127602-25-004871 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,493,897 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vesting of the 2022 PSUs. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:06 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantCommon Stock | 13,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004871 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500,297 F1 · kind: The reported transaction is the vesting of performance-based restricted stock units granted to the reporting person on March 1, 2022 (the "2022 PSUs"). Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:12 UTC | Moderna, Inc. MRNA · Entity 2025 | OtherCommon Stock | 26,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-018819 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,487,064 F1 · kind: Represents the receipt of shares by the reporting person pursuant to pro rata distributions-in-kind, without consideration, of shares of the company's common stock by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") to the partners of Flagship Fund IV and by its general partner, Flagship Ventures Fund IV General Partner, LLC. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:29 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 151,943 | $0.00 Strike: $96.20 | $0.00 |
DisclosureSEC source: 0001127602-24-007620 · form4.xml · derivative · entry 4 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,943 Underlying: Common Stock · 151,943 shares Expires 2034-02-27 F3 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 16, 2024 Filed Feb 16, 2024 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 26,351 | $88.88 | $2,342,097.96 |
DisclosureSEC source: 0001127602-24-005355 · form4.xml · nonDerivative · entry 4 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,460,224 F4 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the 2021 PSUs. This "sell-to-cover" transaction was mandated by the Issuer's equity incentive plan and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantCommon Stock | 56,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-005355 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,486,575 F3 · kind: The reported transaction is the vesting of performance-based restricted stock units granted to the reporting person on March 5, 2021 (the "2021 PSUs"). Read SEC document |
| September 15, 2023 Filed Sep 15, 2023 23:28 UTC | Moderna, Inc. MRNA · Entity 2025 | OtherCommon Stock | 17,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-024257 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,429,839 F2 · kind: Represents the receipt of shares by the reporting person pursuant to pro rata distributions-in-kind, without consideration, of shares of the company's common stock by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") to the partners of Flagship Fund IV and by its general partner, Flagship Ventures Fund IV General Partner, LLC. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:51 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,155 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001127602-23-019642 · form4.xml · derivative · entry 8 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,155 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. F8 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:51 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 366 | $123.05 | $45,036.30 |
DisclosureSEC source: 0001127602-23-019642 · form4.xml · nonDerivative · entry 6 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,411,946 F2 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.98 to $123.13. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:51 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 13,094 | $122.01 | $1,597,598.94 |
DisclosureSEC source: 0001127602-23-019642 · form4.xml · nonDerivative · entry 5 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,412,312 F2 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $121.79 to $122.78. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:51 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 11,417 | $121.40 | $1,386,023.80 |
DisclosureSEC source: 0001127602-23-019642 · form4.xml · nonDerivative · entry 4 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,425,406 F2 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $120.78 to $121.78. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:51 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,278 | $120.39 | $274,248.42 |
DisclosureSEC source: 0001127602-23-019642 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,436,823 F2 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $119.77 to $120.77. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:51 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 27,155 | $0.99 | $26,883.45 |
DisclosureSEC source: 0001127602-23-019642 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,439,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 20:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001127602-23-019319 · form4.xml · derivative · entry 10 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,155 Underlying: Common Stock · 40,000 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. F8 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 20:03 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 15,171 | $119.87 | $1,818,547.77 |
DisclosureSEC source: 0001127602-23-019319 · form4.xml · nonDerivative · entry 8 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,411,946 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $119.49 to $120.41. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 20:03 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 24,829 | $119.13 | $2,957,878.77 |
DisclosureSEC source: 0001127602-23-019319 · form4.xml · nonDerivative · entry 7 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,427,117 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $118.48 to $119.48. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 20:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 40,000 | $0.99 | $39,600.00 |
DisclosureSEC source: 0001127602-23-019319 · form4.xml · nonDerivative · entry 6 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,451,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001127602-23-019319 · form4.xml · derivative · entry 9 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,155 Underlying: Common Stock · 40,000 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. F8 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:03 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 19,289 | $122.21 | $2,357,308.69 |
DisclosureSEC source: 0001127602-23-019319 · form4.xml · nonDerivative · entry 5 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,411,946 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.03 to $122.88. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:03 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 20,711 | $121.77 | $2,521,978.47 |
DisclosureSEC source: 0001127602-23-019319 · form4.xml · nonDerivative · entry 4 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,431,235 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $121.02 to $122.01. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 40,000 | $0.99 | $39,600.00 |
DisclosureSEC source: 0001127602-23-019319 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,451,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:15 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001127602-23-018865 · form4.xml · derivative · entry 14 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,155 Underlying: Common Stock · 40,000 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. F12 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:15 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 14,277 | $129.77 | $1,852,726.29 |
DisclosureSEC source: 0001127602-23-018865 · form4.xml · nonDerivative · entry 12 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,411,946 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $129.51 to $130.13. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:15 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 7,115 | $129.12 | $918,688.80 |
DisclosureSEC source: 0001127602-23-018865 · form4.xml · nonDerivative · entry 11 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,426,223 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $128.50 to $129.49. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:15 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 8,443 | $127.99 | $1,080,619.57 |
DisclosureSEC source: 0001127602-23-018865 · form4.xml · nonDerivative · entry 10 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,433,338 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $127.40 to $128.38. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:15 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,377 | $127.01 | $682,932.77 |
DisclosureSEC source: 0001127602-23-018865 · form4.xml · nonDerivative · entry 9 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,441,781 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $126.38 to $127.38. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:15 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 4,788 | $125.61 | $601,420.68 |
DisclosureSEC source: 0001127602-23-018865 · form4.xml · nonDerivative · entry 8 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,447,158 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $125.15 to $125.98. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:15 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 40,000 | $0.99 | $39,600.00 |
DisclosureSEC source: 0001127602-23-018865 · form4.xml · nonDerivative · entry 7 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,451,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:15 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001127602-23-018865 · form4.xml · derivative · entry 13 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,155 Underlying: Common Stock · 40,000 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. F12 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.